Liquidity ratios measure the company ability to meet its short-term obligations.
Paying user area
Try for free
Regeneron Pharmaceuticals Inc. pages available for free this week:
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Enterprise Value (EV)
- Price to FCFE (P/FCFE)
- Selected Financial Data since 2005
- Operating Profit Margin since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Revenues
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Regeneron Pharmaceuticals Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Liquidity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
The liquidity position, as indicated by the current, quick, and cash ratios, demonstrates a generally strong, though evolving, profile over the observed period. Initial values are robust, followed by a period of fluctuation and a subsequent moderate decline towards the end of the analyzed timeframe.
- Current Ratio
- The current ratio exhibits a pattern of initial increase from 4.76 in March 2022 to a peak of 5.69 in December 2022. Following this peak, the ratio experiences a gradual decline, reaching 4.73 in December 2024, before stabilizing slightly at 4.13 in December 2025. This suggests a decreasing ability to cover short-term liabilities with short-term assets, although the ratio remains above 4.0 throughout the period.
- Quick Ratio
- Similar to the current ratio, the quick ratio shows an upward trend initially, increasing from 3.95 to 4.82 between March 2022 and December 2022. A subsequent downward trend is then observed, with the ratio decreasing to 3.28 by December 2025. The quick ratio’s decline mirrors that of the current ratio, indicating a consistent reduction in the ability to meet short-term obligations with the most liquid assets. The ratio remains above 3.0 for most of the period, but the decline is noticeable.
- Cash Ratio
- The cash ratio demonstrates a more stable pattern compared to the current and quick ratios. It fluctuates between 2.34 and 3.17 for the majority of the period. A more pronounced decline is observed towards the end of the timeframe, falling from 2.94 in March 2024 to 1.97 in December 2025. This indicates a reduction in the proportion of current assets held as cash, potentially reflecting strategic deployment of cash reserves or changes in working capital management.
Overall, the observed trends suggest a gradual shift in the liquidity profile. While the ratios consistently indicate a strong liquidity position, the downward trends in the latter part of the period warrant monitoring. The consistent decline across all three ratios suggests this is not an isolated change but a broader pattern in the company’s short-term asset management.
Current Ratio
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||
| Current assets | |||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||
| Current ratio1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Current Ratio, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Current ratio = Current assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The current ratio exhibited a generally positive trend from March 31, 2022, through December 31, 2023, followed by a decline through December 31, 2025. Initial values indicated a strong liquidity position, which subsequently fluctuated but remained above 4.0 for the majority of the observed period.
- Overall Trend
- The current ratio increased from 4.76 in March 2022 to a peak of 5.69 in September 2023. A subsequent downward trend commenced in December 2023, decreasing to 4.13 by December 2025. This suggests a potential weakening in short-term liquidity towards the end of the analyzed timeframe, although the ratio remained within a reasonably healthy range.
- Period of Growth (March 2022 - September 2023)
- From March 2022 to September 2023, the current ratio demonstrated consistent growth, increasing from 4.76 to 5.69. This indicates that current assets grew at a faster rate than current liabilities during this period, strengthening the company’s ability to meet its short-term obligations. The most significant increase occurred between June 2023 and September 2023.
- Period of Decline (December 2023 - December 2025)
- Beginning in December 2023, the current ratio began a decline, falling from 5.69 to 4.13 by December 2025. This suggests that current liabilities grew at a faster rate than current assets during this period. While the ratio remained above 4.0, the downward trend warrants monitoring to ensure continued short-term solvency.
- Quarterly Fluctuations
- Within the overall trends, quarterly fluctuations were observed. For example, a slight decrease occurred between September 2022 and December 2022, and again between December 2022 and March 2023. These fluctuations suggest potential seasonal or cyclical factors influencing the composition of current assets and liabilities.
- Recent Performance
- The most recent two quarters (September 30, 2025 and December 31, 2025) show a stabilization of the current ratio around 4.06 and 4.13 respectively, indicating a possible slowing of the decline observed in prior quarters. However, continued monitoring is necessary to confirm this stabilization.
Quick Ratio
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||
| Marketable securities | |||||||||||||||||||||
| Accounts receivable, net | |||||||||||||||||||||
| Total quick assets | |||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||
| Quick ratio1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Quick Ratio, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The quick ratio for the analyzed period demonstrates generally healthy liquidity, though with some fluctuation. Initially, the ratio exhibits an increasing trend, followed by a period of relative stability, and then a noticeable decline towards the end of the observed timeframe.
- Overall Trend
- The quick ratio began at 3.95 and generally increased through the first half of 2023, peaking at 4.54. From this point, the ratio experienced a gradual decline, falling to 3.28 by the end of the period. This suggests a weakening, though still acceptable, ability to meet short-term obligations with highly liquid assets.
- Initial Increase (Mar 31, 2022 – Jun 30, 2023)
- Between March 31, 2022, and June 30, 2023, the quick ratio increased from 3.95 to 4.54. This improvement coincided with increases in both total quick assets and current liabilities, but the growth in quick assets outpaced that of current liabilities. This indicates an enhanced capacity to cover immediate liabilities without relying on inventory sales.
- Subsequent Decline (Sep 30, 2023 – Dec 31, 2025)
- From September 30, 2023, through December 31, 2025, the quick ratio decreased from 4.31 to 3.28. While quick assets experienced some fluctuation, the increase in current liabilities appears to be the primary driver of this decline. The most significant drop occurred between September 30, 2025, and December 31, 2025, where the ratio fell from 3.19 to 3.28. This suggests a potential strain on short-term liquidity as liabilities grew at a faster rate than liquid assets.
- Peak and Trough Values
- The highest recorded quick ratio was 4.82, observed on December 31, 2022. The lowest recorded quick ratio was 3.19, observed on September 30, 2025. These represent the extremes of the observed liquidity position during the analyzed period.
- Recent Performance
- The most recent two quarters (March 31, 2025 and June 30, 2025) show a quick ratio of 3.90 and 3.57 respectively, continuing the downward trend. This suggests that the company’s short-term liquidity position requires continued monitoring.
Overall, the quick ratio indicates a generally strong, but recently weakening, short-term liquidity position. The increasing current liabilities relative to quick assets warrant further investigation to understand the underlying causes and potential implications.
Cash Ratio
| Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in thousands) | |||||||||||||||||||||
| Cash and cash equivalents | |||||||||||||||||||||
| Marketable securities | |||||||||||||||||||||
| Total cash assets | |||||||||||||||||||||
| Current liabilities | |||||||||||||||||||||
| Liquidity Ratio | |||||||||||||||||||||
| Cash ratio1 | |||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||
| Cash Ratio, Competitors2 | |||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||
Based on: 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q4 2025 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= ÷ =
2 Click competitor name to see calculations.
The cash ratio for the analyzed period demonstrates overall stability with fluctuations throughout the observed timeframe. Initially, the ratio exhibited an increasing trend, peaking in late 2022, before experiencing a gradual decline through the end of the forecast period.
- Initial Trend (Mar 31, 2022 – Dec 31, 2022)
- The cash ratio began at 2.34 and increased to 2.49 by June 30, 2022. A slight decrease to 2.44 was noted in September 2022, followed by a recovery to 2.46 by the end of the year. This initial period suggests a strengthening of the company’s immediate liquidity position.
- Peak and Subsequent Decline (Mar 31, 2023 – Dec 31, 2024)
- The ratio peaked at 2.89 in March 2023, representing the highest point in the analyzed period. From this peak, a consistent, though moderate, downward trend was observed, falling to 2.28 by December 2024. This decline indicates a relative decrease in the proportion of cash available to cover current liabilities.
- Recent Fluctuations (Mar 31, 2025 – Dec 31, 2025)
- The ratio experienced a slight increase from 2.04 in March 2025 to 1.97 in December 2025, interrupting the prior downward trend. However, the ratio remained below the levels observed in the earlier part of the period. This suggests potential stabilization at a lower level of immediate liquidity.
- Underlying Components
- Total cash assets generally increased from March 2022 to December 2022, then continued to increase through September 2023, before beginning a decline. Current liabilities also exhibited an overall increasing trend throughout the period, contributing to the observed decrease in the cash ratio after September 2023. The ratio’s movement is therefore a function of both cash asset and current liability changes.
In summary, while the company consistently maintained a cash ratio above 2.0 for most of the analyzed period, the recent downward trend warrants monitoring. The ability to cover short-term obligations with available cash decreased over time, although the company still appears to have a comfortable cushion.